Eukedos S.p.A. (IT:EUK)
:EUK
Want to see IT:EUK full AI Analyst Report?
Top Page
Eukedos S.p.A.
(EUK)
Select Model
Select Model
Rating:45Neutral
Price Target:
€0.62
▼(-14.03% Downside)
Action:ReiteratedDate:04/23/26
The score is primarily constrained by weak financial quality: recent net losses, highly leveraged balance sheet, and volatile free cash flow despite steady operating margins and positive operating cash flow. Technicals are mixed with only a modest recent improvement, while valuation is less supportive due to a negative P/E.
Positive Factors
Stable operating margins
Consistent EBITDA (≈20–25%) and EBIT (≈9–11%) margins indicate the core care-service operations generate recurring operating profitability. Over a multi-month horizon this supports resilience to demand swings, underpinning cash generation and the ability to fund operational needs without immediate structural change.
Negative Factors
Very high leverage
A debt-to-equity ratio in the 3.3x–4.4x range with rising 2025 debt materially increases refinancing, covenant and interest-rate risk. Over the coming months high leverage constrains strategic flexibility, raises likelihood of higher funding costs, and makes the company sensitive to cash-flow volatility or adverse funding markets.
Read all positive and negative factors
Positive Factors
Negative Factors
Stable operating margins
Consistent EBITDA (≈20–25%) and EBIT (≈9–11%) margins indicate the core care-service operations generate recurring operating profitability. Over a multi-month horizon this supports resilience to demand swings, underpinning cash generation and the ability to fund operational needs without immediate structural change.
Read all positive factors
Eukedos S.p.A. (EUK) vs. iShares MSCI Italy ETF (EWI)
Market Cap
€15.35M
Dividend YieldN/A
Average Volume (3M)4.68K
Price to Earnings (P/E)―
Beta (1Y)0.30
Revenue Growth2.31%
EPS Growth-43.04%
CountryIT
Employees483
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)N/A
Shares Outstanding22,741,629
10 Day Avg. Volume3,064
30 Day Avg. Volume4,678
Financial Highlights & Ratios
PEG Ratio-0.50
Price to Book (P/B)0.55
Price to Sales (P/S)0.31
P/FCF Ratio36.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Eukedos S.p.A. Business Overview & Revenue Model
Company Description
EuKedos S.p.A. provides managed and long-term care services in Italy. The company offers residential social care services to elderly, self-sufficient, or incapacitated adults. It manages healthcare and assistance residences with 1,345 beds in the ...
How the Company Makes Money
Eukedos makes money primarily by providing social and healthcare services and being paid for the management and delivery of those services (e.g., operating care facilities and/or providing care-related services under contractual arrangements). Rev...
Eukedos S.p.A. Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
29
Negative
Cash Flow
41
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 51.64M | 51.69M | 49.45M | 47.04M | 45.18M |
| Gross Profit | 12.09M | 48.96M | 13.73M | 32.03M | 32.99M |
| EBITDA | 10.26M | 12.27M | 12.41M | 10.87M | 10.72M |
| Net Income | -749.00K | -524.00K | 556.00K | 443.00K | 570.00K |
Balance Sheet | |||||
| Total Assets | 180.33M | 179.34M | 149.10M | 153.38M | 150.08M |
| Cash, Cash Equivalents and Short-Term Investments | 416.00K | 3.91M | 2.33M | 3.62M | 7.39M |
| Total Debt | 128.29M | 99.02M | 105.83M | 111.45M | 108.95M |
| Total Liabilities | 151.23M | 149.50M | 119.19M | 123.99M | 121.26M |
| Stockholders Equity | 29.10M | 29.84M | 29.91M | 29.39M | 28.82M |
Cash Flow | |||||
| Free Cash Flow | 436.00K | -13.14M | 3.59M | 1.03M | 5.31M |
| Operating Cash Flow | 6.24M | 9.94M | 10.08M | 5.18M | 5.61M |
| Investing Cash Flow | -5.86M | -58.49M | -8.92M | -4.15M | -306.00K |
| Financing Cash Flow | -3.87M | 50.13M | -2.45M | -4.79M | -562.00K |
Eukedos S.p.A. Technical Analysis
Positive
0.72
Price Trends
0.62
Positive
0.67
Negative
0.71
Negative
Market Momentum
<0.01
Negative
61.59
Neutral
89.25
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:EUK, the sentiment is Positive. The current price of 0.72 is above the 20-day moving average (MA) of 0.56, above the 50-day MA of 0.62, and above the 200-day MA of 0.71, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 61.59 is Neutral, neither overbought nor oversold. The STOCH value of 89.25 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:EUK.
Eukedos S.p.A. Peers Comparison
UnderperformOutperform
Sector (51)
IT:EUK
Eukedos S.p.A.
0.68
-0.08
-11.18%
IT:ARBS
Arterra Bioscience SpA
3.09
0.84
37.33%
IT:COSMO
Farmacosmo S.P.A.
0.44
-0.19
-29.87%
IT:TALEA
Farmae SpA
4.80
-0.22
-4.38%
IT:ERFO
Laboratorio Farmaceutico Erfo SpA
1.17
0.07
6.88%
IT:SVS
Svas Biosana S.p.A.
9.16
1.79
24.29%
Eukedos S.p.A. Corporate Events
Eukedos Publishes 2025 Annual Report and Governance Documents Ahead of April Shareholder Meeting
Apr 7, 2026
Eukedos S.p.A. has published its Annual Financial Report for the year ended 31 December 2025, including separate and consolidated financial statements, the management report, and accompanying auditors’ and statutory auditors’ reports. ...
Eukedos edges up revenues in 2025 but widens net loss amid high debt
Mar 30, 2026
Eukedos S.p.A. has approved its 2025 draft separate and consolidated financial statements, reporting a consolidated value of production of €52.9 million, up from €51.6 million a year earlier, driven mainly by the Care Area’s 2.1%...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.